Skip to main content

EsoCap impresses investors

| News

EsoCap impresses investors

25.11.2021

EsoCap, a biotech company based in Basel, has concluded a successful funding round. The funds from new and existing investors are to be used to drive forward a phase II clinical trial of a treatment for esophageal disorders.

EsoCap develops forms of treatment for diseases of the upper gastrointestinal tract, which also includes the esophagus. According to a press release, the Basel-based biotech company will now push forward with a phase II clinical trial on a treatment for eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus. It is using fresh funds from a financing round initiated by the Canton of Basel-Stadt to do so.

The canton started a corresponding initiative to support companies during the coronavirus pandemic. EsoCap applied as a participant for this and was accepted. Both new and existing investors were involved in the subsequent funding round. Isabelle Racamier, CEO of EsoCap, comments in the press release: “We are proud to have the confidence of the Canton of Basel-Stadt and private investors.”

Medication to treat esophageal disorders only has a few seconds for its effect to act locally when moving from the mouth through the esophagus into the stomach. This is why EsoCap hopes to improve administration. The platform developed for this should not only help those with eosinophilic esophagitis but also other diseases such as Barrett’s esophagus or acid reflux. According to Racamier, there is a high need for suitable treatments in this area. EsoCap’s lead product candidate, ESO-101, has already received orphan drug status from the American regulatory authority, the Food and Drug Administration, meaning that it is a recognized treatment option for a rare disease.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.